ADX 324
Alternative Names: ADX-324Latest Information Update: 26 Feb 2024
At a glance
- Originator ADARx Pharmaceuticals
- Class Oligonucleotides; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hereditary angioedema
Most Recent Events
- 09 Nov 2023 Pharmacodynamics data from a preclinical trial in Hereditary angioedema presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2023)
- 14 Dec 2022 Phase-I clinical trials in Hereditary angioedema (In volunteers) in USA (Parenteral) (NCT05691361)
- 28 Sep 2022 ADARx Pharmaceuticals plans a phase-I trial for Hereditary angioedema (Parenteral) at the end of 2022